Omnipaque Mechanism of Action

Pharmacology: Pharmacodynamics: For most of the haemodynamic, clinical-chemical and coagulation parameters examined following intravenous injection of iohexol in healthy volunteers, no significant deviation from preinjection values has been found. The few changes observed in the laboratory parameters were minor and considered to be of no clinical importance.
Pharmacokinetics: Close to 100 percent of the intravenously injected iohexol is excreted unchanged through the kidneys within 24 hours in patients with normal renal function. The maximum urinary concentration of iohexol appears within approximately 1 hour after injection.
The elimination half-life is approximately 2 hours in patients with normal renal function. No metabolites have been detected. The protein binding of Omnipaque is so low (less than 2%), that it has no clinical relevance and can therefore be neglected.
Toxicology: Preclinical Safety Data: Iohexol has a very low acute intravenous toxicity in mice and rats. Animal studies have shown that iohexol has a very low protein binding, and is well tolerated by the kidneys. The cardiovascular and neurotoxicity are low. The histamine release ability and the anticoagulant activity have been shown to be less than for ionic contrast media.